Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Icecure Medical ( (ICCM) ) is now available.
On September 15, 2025, IceCure Medical announced it received regulatory approval in Israel for its next-generation XSense™ Cryoablation System, which is designed for treating breast cancer and other medical indications. This approval by Israel’s Ministry of Health reinforces IceCure’s leadership in cryoablation technology and is expected to enhance the company’s market position by offering a minimally invasive treatment option that reduces costs and accelerates recovery for patients.
The most recent analyst rating on (ICCM) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Icecure Medical stock, see the ICCM Stock Forecast page.
Spark’s Take on ICCM Stock
According to Spark, TipRanks’ AI Analyst, ICCM is a Neutral.
Icecure Medical’s overall stock score is primarily impacted by its financial performance, which is currently weak due to declining revenues and substantial losses. While there are positive developments in regulatory progress and clinical achievements, these are overshadowed by financial challenges. Technical analysis and valuation also present concerns, with mixed signals and a negative P/E ratio. The company’s future prospects hinge on strategic improvements and successful regulatory outcomes.
To see Spark’s full report on ICCM stock, click here.
More about Icecure Medical
IceCure Medical, listed on Nasdaq as ICCM, is a company that develops and markets advanced cryoablation therapy systems using liquid nitrogen to destroy tumors. Their minimally invasive technology focuses on treating breast, kidney, bone, and lung cancers, offering a safe alternative to traditional surgical tumor removal. The company’s flagship system, ProSense®, is marketed globally.
Average Trading Volume: 1,653,297
Technical Sentiment Signal: Sell
Current Market Cap: $67.7M
For a thorough assessment of ICCM stock, go to TipRanks’ Stock Analysis page.